Article

A Retrospective Study of the Diagnostic Accuracy of Fine-Needle Aspiration for Breast Lesions and Implications for Future Use

Department of Pathology and Lab Medicine, David Geffen Medical School, Center of Health Science, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA.
Diagnostic Cytopathology (Impact Factor: 1.52). 12/2008; 36(12):855-60. DOI: 10.1002/dc.20933
Source: PubMed

ABSTRACT In recent years, the use of fine-needle aspiration (FNA) in the diagnosis of breast lesions has declined in many institutions. We sought to evaluate the role of FNA for breast lesions and the annual rate of the procedure at our institution over a 4(1/2) year period (May 2002-October 2006). A total of 831 FNAs were performed, with 258 (31%) having histologic follow-up. The number of FNAs obtained was 159 from 5/02 to 4/03, 192 from 5/03 to 4/04, 194 from 5/04 to 4/05, 191 from 5/05 to 4/06, and 95 from 5/06 to 10/06. Each case was placed into one of four categories: nondiagnostic (9%), benign (77.5%), atypical/suspicious (5.5%), or malignant (8%). Surgical tissue was available for 37% of nondiagnostic cases, 22% of benign cases, 80% of atypical/suspicious cases, and 72% of malignant cases. The overall sensitivity and specificity for FNA was 83 and 92% respectively. The overall positive and negative predictive values were 83 and 92% respectively. There were no false-positive cases, indicating a positive predictive value of 100% for a Dx of malignancy. For cases with surgical follow-up, the false-negative rate was 5.4%. Although there is a national trend away from FNAs of breast lesion, this has not been the experience at our institution. Although FNA may not be ideal in the initial evaluation of suspicious lesions, we argue that FNA for clinically benign palpable lesions and recurrent carcinomas has significant value.

0 Followers
 · 
45 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Triple assessment is a standard method for assessment of breast diseases, which includes clinical evaluation, radiographic assessment and pathological assessment. Biopsy for breast disease is the gold standard for pathological assessment, including incisional biopsy, excisional biopsy, core needle biopsy, vacuum-assisted biopsy and bite biopsy. With the continuous advancement of diagnostic and treatment technology for breast cancer, collection of diseased tissue has also undergone a gradual transition from traditional open surgery to biopsy. This review summarizes the current situation and development of breast biopsy technology to provide an insight into the latest details such as the safety and reliability as the basis for selection of the most appropriate techniques for specific settings.
  • [Show abstract] [Hide abstract]
    ABSTRACT: common malignant neoplasm (next to cervical cancer) in females, comprising 22.2% of all new cancer diagnoses and 17.2% of all cancer deaths. [2] The management of breast disease needs a deliberate, synchronized diagnostic and treatment strategy. Fine-needle aspiration cytology (FNAC) is an important diagnostic tool for the preoperative diagnosis of palpable and non-palpable breast lesions. The procedure has advantages in that it provides rapid and accurate diagnosis and serves a cost-effective tool for the treatment of breast masses. [3] It differentiates cysts from a solid tumor and can be used as a therapeutic procedure when a cyst is encountered. Whenever a malignancy is diagnosed, it permits participation of the patient in the decision-making process. It also provides a psychological relief to the patients once diagnosed with benign breast lesions. In addition, it is useful for evaluation of local chest wall recurrences and Background: Fine-needle aspiration cytology (FNAC) has been established as a highly accurate diagnostic technique over the past few decades. It is a rapid, reliable, and safe initial diagnostic tool used for both non-neoplastic and neoplastic breast lesions.
    02/2015; 4(5 1). DOI:10.5455/ijmsph.2015.31122014139
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast lumps constitute a significant proportion of surgical cases in women of both developed and developing countries. The aim of this study is to look the frequency distribution of various breast lesions on fine needle aspiration (FNA). The 902 patients who presented with palpable breast lump, irrespective of age and sex were included in the study. Frequency distribution of various breast lesions with respect to age and sex was studied. Cytology grading in breast carcinoma was correlated in 69 cases with histology grading. The majority (N = 871) of patients were females with maximum (N = 566) patients between second and third decade. The 773 patients had benign breast lesions and maximum (N = 341) patients were in the second decade. Fibroadenoma was the commonest benign lesion followed by fibrocystic change and mastitis. Out of 119 malignant breast lesions, 31.93% [N = 38] were between 41-50 years of age, 28.57% [N = 34] in 51-60 years and 22.68% [N = 27] in between 31-40 years of age. Out of 119 malignant breast lumps and majority were infiltrating ductal carcinoma (N = 108). Cytology grading correlated maximum with histology grade in Grade I followed by Grade II and Grade III. With experienced hands, FNA is safe, cost effective and a reliable technique for preoperative evaluation of palpable breast lumps. FNA features are more informative when combined with physical and radiology findings (Triple test). Fibroadenoma, fibrocystic change and mastitis form the major bulk of benign breast lesions. Epithelioid cells when seen in inflammatory breast FNA smears, tuberculosis must be ruled out. In India, breast carcinoma arises in younger patients as compared to western countries. Grading of breast carcinomas must be done on FNA smears for selecting neoadjuvent therapy. Clinical breast examination and mammography screening in females should be encouraged in developing countries from the third decade onwards for early detection of breast carcinoma.
    10/2014; 5(4):186-91. DOI:10.4103/0976-7800.145164